Levin Capital Strategies’s Acadia Pharmaceuticals ACAD Stock Holding History

Levin Capital Strategies’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-17,399	Closed	-$485K	–	345
2017 Q2	$485K	Sell	17,399 -4,513	-21%	-$134K	0.01%	199
2017 Q1	$753K	Buy	+21,912	New	+$773K	0.01%	169
2016 Q4	–	Sell	-12,000	Closed	-$382K	–	304
2016 Q3	$382K	Buy	+12,000	New	+$407K	0.01%	250
2016 Q2	–	Sell	-7,904	Closed	-$221K	–	338
2016 Q1	$221K	Buy	+7,904	New	+$172K	﹤0.01%	299
2015 Q3	–	Sell	-5,000	Closed	-$209K	–	366
2015 Q2	$209K	Sell	5,000 -20,000	-80%	-$774K	﹤0.01%	358
2015 Q1	$815K	Buy	+25,000	New	+$859K	0.01%	235

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Levin Capital Strategies's ACAD Position: Q3 2017 in Review

Levin Capital Strategies sold out of Acadia Pharmaceuticals (ACAD) in Q3 2017, closing a stake of 17,399 shares — an estimated $485K sold.

Levin Capital Strategies first reported a position in ACAD in Q1 2015 and held it in 6 quarters. The position peaked at $815K in Q1 2015. 212 funds tracked by Wall St. Rank hold ACAD as of Q3 2017.

Levin Capital Strategies reported no remaining Acadia Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Levin Capital Strategies sold 17,399 Acadia Pharmaceuticals shares in Q3 2017, an estimated $485K.
Levin Capital Strategies first reported a position in Acadia Pharmaceuticals in Q1 2015 and held it in 6 quarters.
Levin Capital Strategies's Acadia Pharmaceuticals position peaked at $815K in Q1 2015.
212 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2017.

Based on Levin Capital Strategies's 13F filing for Q3 2017, filed 13 Nov 2017.